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Breast cancer therapy has moved from more to less
invasive methodologies, with greater emphasis on image-
guided interventions that minimize toxicity and deformity.
Defining the standard of care for breast cancer diagnosis
and treatment is a means of elevating quality on a national
level. This is a dynamic process, requiring constant eval-
uation of emerging technologies and clinical trial data.
Dissemination and adoption of changing standards relate to
many barriers, including access to care, geographic prox-
imity to treatment facilities, reimbursement levels, and
equipment expenses.
The era of a surgical evaluation consisting of an exci-
sional biopsy or a needle-localized excision has become an
historical footnote for most presentations of breast cancer.
Many surgeons have also transitioned from palpation-gui-
ded needle biopsy to ultrasound-guided biopsy to increase
the accuracy of their sampling procedure. Exceptions for
the use of these approaches remain, but they have become
rare and will continue to become less applicable. Initial
core needle sampling is appropriately followed by surgical
excision for discordant pathology, atypical ductal or lob-
ular hyperplasia, lobular carcinoma-in-situ, incompletely
ablated papillary lesions, and radial scars. Technical factors
may limit the use of a needle biopsy, including inaccessible
areas in proximity to the skin, chest wall, or prosthetic
implant. Faint microcalcifications may not be amenable to
stereotactic core needle biopsy. An initial open procedure
is also appropriate for patients with nipple discharge in the
absence of radiographic abnormalities, patients who
require excision of benign-appearing lesions, and patients
with suspicious lesions and comorbities that require
chronic anticoagulation or that diminish the impact of
axillary staging.
For most breast cancer patients, Pocock and colleagues
have enumerated much of the data showing favorable
outcomes for needle diagnosis of breast cancer.1 These
include reductions in operating room time, exposure to
anesthesia, risk of infection, margin-positive excisions,
lumpectomy extent and cosmetic deformity, and false-
positive sentinel node biopsy. Patient preference has been
described as a reason for initial excision. However, a
rational review of these endpoints should be sufficient to
persuade most patients to proceed with a needle diagnosis.
Recognizing that a preoperative needle diagnosis offers
many compelling advantages over an open procedure, it is
a useful criterion for quality. In the report of Pocock et al.,
the retrospective retrieval of biopsy data for 396 patients
took 10 hours, leading to an average of 1.5 min of time per
patient.1 These data can be captured from a variety of
sources, including medical reports and billing records.
Thus, this criterion is both useful and readily accessible.
Other proposed criteria for quality include the use of irra-
diation after breast-conserving surgery, adjuvant
chemotherapy, adjuvant hormonal therapy, axillary evalu-
ation in early-stage breast cancer, and conformity with the
College of American Pathology reporting.2
As improvements in care are identified and the electronic
medial record emerges, reimbursement has become easier to
connect with quality endpoints. The National Cancer Data
Base (NCDB) represents one data repository that collects
information on 70% of the cancers treated in the United
States. Treatment and pathology variables are entered into
the NCDB, including use of radiation therapy, chemother-
apy, hormone therapy, and axillary staging. With more
sophisticated electronic data submission methods, inclusion
of the diagnostic technique should be an attainable addition.
This endpoint should be measurable for hospitals, breast
treatment centers, and individual practitioners. One
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potential mechanism for monitoring this endpoint at breast
centers is through the National Accreditation Program of
Breast Centers (NAPBC), a consortium of organizations
involved in the care of breast cancer. The NAPBC has
established 27 standards for evaluation and management,
one of which is percutaneous needle biopsy. Compliance is
verified by a site survey conducted every 3 years. By
reviewing pathology reports, the surveyor can determine
how the initial diagnosis was made and allow for justifiable
exceptions. These standards also include the presence of a
qualified or certified physician performing image-guided
biopsies as determined by either the American College of
Radiology or the American Society of Breast Surgeons.
These criteria provide an opportunity to track, measure,
and maintain quality on a large scale.
The usefulness of a preoperative needle biopsy does not
appear to be related to stage or presentation, avoiding any
interpretative inconsistencies related to geography or delay
in diagnosis. On the basis of the report of Pocock et al. and
those of others, a reasonable target for PND compliance
would be 85%, leaving room for appropriate exceptions.1,3
Measuring this benchmark (among others) will help the
treating facility, physicians, and patients to recognize and
maintain high-quality care in the treatment of breast
cancer.
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